Dr. Reddy's Laboratories has marked its entry into the hormone replacement therapy (HRT) space with the acquisition of trademarks for specialty brands Progynova and Cyclo-Progynova, along with related assets in India, from UK-based Mercury Pharma Group for $32.15 million, according to media reports.
Progynova (estradiol valerate) is an oral hormone replacement therapy used to treat symptoms of estrogen deficiency and help prevent postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined HRT indicated for estrogen deficiency symptoms, offering both estrogen and progestogen components.
